Tenderwize
Wróć do wyszukiwania

Biologic rebate contracts for insulin-isophan

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2027 · 339 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-12 - Insulin-isophan (human)

60/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

60 / 100

Złożoność

40 / 100

Czynniki ryzyka

No estimated contract value or framework maximum value is disclosed. Participants cannot assess potential revenue.

Open house procedure means all eligible pharmaceutical entrepreneurs can join, potentially leading to many participants...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 2 lots
  • Duration until Jul 2027
  • Supply of Insulin-isophan (human) pharmaceutical products
  • Conclusion of discount agreements (Rabattverträge) according to §130a Abs. 8 SGB V
Pokaż pełne podsumowanie

Open House procedure by Techniker Krankenkasse (TK) and other health insurers for discount agreements on Insulin-isophan (human) in two dosage forms: cylinder ampoules and pre-filled pens. The procedure is open to all eligible pharmaceutical entrepreneurs meeting specific criteria under German law. No exclusivity is guaranteed; contracts are concluded with all qualifying bidders on standard terms. The contract term is 24 months starting August 1, 2025, ending July 31, 2027. No estimated contract value is provided. Submission is possible at any time during the contract period via email (with qualified electronic signature) or post.

Ryzyka

No estimated contract value or framework maximum value is disclosed. Participants cannot assess potential revenue.

Open house procedure means all eligible pharmaceutical entrepreneurs can join, potentially leading to many participants...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG with valid marketing authorization for the product
  • Registered seat in Germany, EU, or EEA

Eligibility

  • No convictions or events triggering exclusion under §§123, 124 GWB within last 3-5 years

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (2)

LOT-0001

Insulin-isophan (human) - Cylinder Ampoules

Discount agreement for Insulin-isophan (human) in cylinder ampoules dosage form. Open to all eligible pharmaceutical entrepreneurs meeting the requirements of §130a Abs. 8 SGB V.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Jul 2025 - Jul 2027

Kategoria

Pharmaceutical products

Termin

Deadline Jul 30, 2027

LOT-0002

Insulin-isophan (human) - Pre-filled Pen

Discount agreement for Insulin-isophan (human) in pre-filled pen dosage form. Open to all eligible pharmaceutical entrepreneurs meeting the requirements of §130a Abs. 8 SGB V.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Jul 2025 - Jul 2027

Kategoria

Pharmaceutical products

Termin

Deadline Jul 30, 2027

Szczegóły zamówienia

Data publikacji
11 May 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
298227-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3